Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Naive Cohort (people who have never been treated for CLL):
- People who have been officially diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) according to 2018 international medical guidelines
- People aged 18 years or older
- People who have never received any treatment for CLL
Venetoclax-Treatment Cohort (people previously treated with venetoclax):
- People who have been officially diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) according to 2018 international medical guidelines
- People who have taken the drug venetoclax (at any dose) for at least 12 months, with the last dose taken no more than 12 months before registering for the trial
Who may not be able to join:
- People who have had a severe allergic reaction to a pneumococcal (pneumonia) vaccine in the past
- People who have received a specific type of pneumococcal vaccine (called PCV13 or PCV20) within the last five years (note: people who received a different pneumococcal vaccine called PPSV23 at least one year ago, and no other pneumococcal vaccine, may still be eligible — confirm with trial site)
- People who currently have an active infection being treated with antibiotic medication
- People who have used immune-suppressing medications within 14 days of starting the trial, with some exceptions for certain low-dose or locally applied steroids (confirm with trial site)
- People with another illness or condition that the treating doctor believes would negatively affect their ability to take part in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel Ermann, MD, Huntsman Cancer Institute/ University of Utah
Phone: 801-587-4713
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients who achieve the protocol defined change in antibody titers
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.